Quantitative Investment Management LLC Purchases 19,359 Shares of Danaher Corporation $DHR

Key Points

• Quantitative Investment Management LLC increased its stake in Danaher Corporation by 58.0%, owning 52,711 shares valued at approximately $10.8 million.
• Danaher reported an earnings per share (EPS) of $1.80 for the last quarter, beating analysts' estimates by $0.16, with revenues of $5.94 billion.
• Seventeen analysts rated Danaher as a Buy, with a consensus target price of $247.61, reflecting positive sentiment in the stock's future performance.

Quantitative Investment Management LLC boosted its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 58.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,711 shares of the conglomerate's stock after purchasing an additional 19,359 shares during the period. Danaher comprises about 1.0% of Quantitative Investment Management LLC's portfolio, making the stock its 19th largest holding. Quantitative Investment Management LLC's holdings in Danaher were worth $10,805,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. FAS Wealth Partners Inc. increased its holdings in Danaher by 20.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after buying an additional 1,639 shares during the last quarter. MGO One Seven LLC raised its holdings in shares of Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after purchasing an additional 20,813 shares during the period. Asahi Life Asset Management CO. LTD. acquired a new stake in Danaher in the 1st quarter valued at about $539,000. Horizon Financial Services LLC grew its holdings in Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after purchasing an additional 8,160 shares during the period. Finally, EFG Asset Management Americas Corp. increased its position in Danaher by 13.1% during the first quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate's stock worth $7,396,000 after buying an additional 4,191 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Performance

Danaher stock traded up $0.42 during midday trading on Thursday, hitting $205.42. The company's stock had a trading volume of 2,519,735 shares, compared to its average volume of 4,185,368. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company has a market cap of $147.09 billion, a price-to-earnings ratio of 43.71, a PEG ratio of 2.88 and a beta of 0.73. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The company has a 50-day moving average price of $201.23 and a two-hundred day moving average price of $199.46.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the prior year, the business posted $1.72 EPS. The business's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Barclays reaffirmed an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Robert W. Baird upped their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, Danaher currently has an average rating of "Moderate Buy" and an average target price of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.